Phase I/IIa Trial to Evaluate AVX001 Gel in Doses of 1% or 3% Compared With Vehicle Over Four Weeks of Field-directed Treatment Period in Adult Subjects With AK

PHASE1/PHASE2UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 2, 2021

Primary Completion Date

March 31, 2022

Study Completion Date

March 31, 2022

Conditions

Actinic Keratoses

Interventions

DRUG

AVX001

Topical gel treatment for once daily application

Trial Locations (1)

Bispebjerg Hospital, Copenhagen